Omics TRIZ Cases

Multiple protease digestions plus high-resolution mass spectrometry raise protein sequence coverage to distinguish proteoforms and modifications.

Protein measurement in uterine fluid replaces biopsy-based receptivity testing, enabling same-cycle embryo transfer planning with high accuracy.

Ceramide and phosphatidylcholine measurements improve cardiovascular risk stratification when LDL-C and HDL-C leave residual risk unresolved.

Urine biomarkers enable earlier feline CKD staging before clear clinical signs, while targeted nutrition helps slow disease progression.

Combining CRP, IL-6, PDGF-AB/BB, VEGF-A, and FTIR analysis improves early fracture-related infection diagnosis from blood samples.

Particles and labeled reference biomolecules improve biomarker quantitation, control enrichment quality, and reduce disease misclassification.

Fluorescently labeled immobilized peptides are sequenced one molecule at a time, enabling identification in complex mixtures.

Multi-marker OMICS ranking turns heterogeneous cell expression data into objective active agent scores and adjusted formulas.

b-Isox precipitation captures misfolded proteins from biofluids for cost-effective, non-invasive detection of prediabetes, diabetes, and cancers.

Affinity reagents target specific protein modifications to quantify proteoforms with high throughput and functional precision in biological samples.

Affinity-reagent arrays profile alpha-synuclein proteoforms at high throughput while preserving sensitivity and reproducibility for Parkinson's evaluation.

Individual proteins are immobilized and iteratively probed with affinity reagents to characterize and quantify diverse proteoforms at high sensitivity.

A brain proteome biochip maps serum autoantibody profiles to improve TBI diagnosis and track neurodegenerative disease progression.

Labeled reference biomolecules calibrate particle enrichment to reduce interference, improve quantitation, and enable real-time mass spectrometry quality control.

Biomarker panels from biosamples replace subjective exams and costly imaging to detect early muscle atrophy and guide personalized rehabilitation.

Pre-label deglycosylation and quenching reduce free dye and enzyme peak interference, improving glycoprotein separation and quantification.

Affinity purification and mass spectrometry isolate peptide:MHC binders to identify off-target peptides with higher specificity for safer immunotherapy.

A ceramide and phosphatidylcholine biomarker panel improves cardiovascular risk stratification beyond LDL-C, including residual risk after statin treatment.

A unified mass spectrometry workflow plus ML curation expands protein, metabolite, and lipid coverage while keeping CV below 10%.

Baseline cytokine profiling and clustering identify PAH patients likely to respond to IL-6 signaling pathway inhibitors.

Specific lipid biomarkers in biological samples support early breast cancer detection where mammograms are less effective for younger women.

Endoglycosidase treatment removes glycans from labeled proteins before electrophoresis, reducing impurity overlap for accurate quantification.

A composite ceramide and phosphatidylcholine panel reveals residual cardiovascular risk beyond LDL-C for treatment guidance.

This case uses quantified biomarkers and control comparisons to identify BOS risk before spirometry becomes reliable.

Mass spectrometry identifies sleep apnea metabolites to support screening, polysomnography decisions, and treatment selection.

LDI MS and Random Forest analysis use 17 serum metabolites to support rapid drug-resistant tuberculosis screening from a small blood sample.

Selective amino acid labeling and Edman degradation identify and quantify individual peptides, including modified or buried N-termini.

Tandem mass spectrometry quantifies serum peptides to distinguish acute ischemic stroke from intracranial hemorrhagic stroke.

Mass spectrometry-based lipidomic profiling compensates for biological variability to improve diagnostic sensitivity for early-stage pancreatic cancer.

Sequential screening criteria and statistical validation correct mass spectrometry errors, ensuring reliable protein abundance measurements.

A peptide array maps protein binding sites through molecular imprinting and sequencing.

A nanofluidic proteomic immunoassay quantifies total and low-abundance protein isoforms in minimal clinical specimens.

Novel lipidomic markers detect cardiovascular complications in coronary artery disease patients not undergoing statin treatment.

Automated image analysis of Congo Red stained urine aggregates predicts preeclampsia risk without physician oversight.

Alkaline treatment releases esterified eicosanoids from blood samples for mass spectrometry measurement.

A microfluidic chip uses a 3D nanostructured porous membrane to collect and analyze urine secretomes for urological cancer diagnosis.

Targeted urine protein analysis identifies early muscle injury markers, enabling timely intervention before renal impairment develops.

A multi-metabolite biomarker platform detects acute coronary syndrome through in-vivo level analysis of specific metabolites.

Metabolomic profiling diagnoses mild traumatic brain and spinal cord injuries by comparing subject metabolite matrices with predetermined control profiles.

Metabolite biomarkers enable precise detection of Mycobacterium avium paratuberculosis infections through mass spectrometry analysis.

Ketone body and fatty acid measurements detect cancer with high accuracy, replacing low-sensitivity protein markers.

Metabolite profiling differentiates disease phases and improves diagnostic accuracy by analyzing specific blood and urine concentrations.

Bead arrays encode reactive sites using unique molecular weight combinations of bound target analytes, eliminating optical or positional encoding complexity.

Affinity purification isolates recombinant proteins from small sample volumes, enabling sensitive variant detection via HPLC or mass spectrometry.

Bead array reactive sites use capture agents to bind protein fragments for multiplexed mass spectrometry analysis.

Segmented cell sorting isolates capture agents binding to specific GPCR active or inactive states, resolving conformational selectivity limits.

Aldehyde releaser inactivates proteases, eliminating refrigeration needs and preventing protein degradation during room temperature storage.

A microfluidic platform measures lectin binding intensity to reconstruct high-resolution glycan profiles at the single-cell level.

D-amino acid standards resist enzymatic cleavage to quantify BNP proteolytic variants, resolving measurement precision issues in cardiovascular diagnostics.

A microwell array coupled to a capture agent array enables spatially encoded multiplexed detection of secreted proteins from isolated single cells.

Urine metabolite analysis identifies urinary stone disease risk, reducing reliance on invasive imaging procedures.